ZIM Laboratories’ wholly owned European subsidiary -- SIA ZIM Laboratories has received Marketing Authorization (MA) from Infarmed (Portugal) - the Portuguese National Authority of Medicines and Health Products for Dimethyl Fumarate (120 mg & 240 mg) Modified Release Capsules in Portugal. This authorisation will facilitate faster approvals in other European Union countries as well as the UK and other markets globally resulting in better commercialisation opportunities.
Dimethyl Fumarate Modified Release Capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS) and are developed using ZIM’s proprietary technology and is bioequivalent to the Innovator’s product.
According to IQVIA, the EU market size for this product in 2023 was approximately $800 million while UK contributed $200 million. Other markets (Ex USA & Japan) contributed $42 million.
ZIM Laboratories manufactures, formulates, and distributes drug delivery systems to develop generic pharmaceutical products.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.90 |
| Dr. Reddys Lab | 1229.80 |
| Cipla | 1236.25 |
| Zydus Lifesciences | 944.20 |
| Lupin | 2313.15 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: